Azrieli Foundation and Canadian PM increase funding to Neurodevelopmental research program

Program supports Canadian neuroscientists conducting work that aims to change the landscape for families facing Fragile X syndrome and Autism.

By
May 11, 2014 15:47
1 minute read.
Stephen Harper, January 20, 2014

Stephen Harper, January 20, 2014. (photo credit: GPO/AMOS BEN GERSHOM)

 
X

Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user uxperience almost completely free of ads
  • Access to our Premium Section and our monthly magazine to learn Hebrew, Ivrit
  • Content from the award-winning Jerusalem Repor
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later Don't show it again

The Azrieli Foundation and Canadian Prime Minister Stephen Harper announced on Sunday an increased funding commitment to the Azrieli Neurodevelopmental Research Program bringing its total investment in partnership with Brain Canada to $15 million.

The research program supports Canadian neuroscientists conducting leading edge translational work that aims to change the landscape for families facing Fragile X syndrome and Autism.  Fragile X, which affects 1 in 4,000 boys and 1 in 6,000 girls, is the most common inherited cause of intellectual disability and the most common known cause of autism.

Be the first to know - Join our Facebook page.


“We know that Canada is home to some of the world’s foremost neuroscientists and that we have the potential to be a world leader in neurodevelopmental research,” said Dr. Naomi Azrieli, Chair and CEO of the Azrieli Foundation.  “By providing scientists with significant financial support, we are providing the lifeblood of advanced research.”

The Azrieli Foundation initially invested NIS 8.7 million in four new research projects: the examination of new medications targeting different biological causes of autism, research into methods to correct or offset the abnormal communication in the brain that characterizes autism and develop new interventional strategies, identification of the earliest signs of autism onset, and the development of non-toxic drugs.

Scientific grants made by the Azrieli Neurodevelopmental Research Program are a joint effort between the Azrieli Foundation, the Brain Canada Foundation and the federal government’s Canada Brain Research Fund, in a public-private partnership funding model.

Related Content

Lab
August 31, 2014
Weizmann scientists bring nature back to artificially selected lab mice

By JUDY SIEGEL-ITZKOVICH